Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 24 Jan 2019 Planned initiation date changed from 31 Jan 2019 to 1 Feb 2019.
    • 03 Jan 2019 Planned initiation date changed from 15 Dec 2018 to 31 Jan 2019.
    • 22 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top